MEI Pharma IncFind Ratings Reports
MEI PHARMA INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Even though it increased sales and net income significantly, the company was unable to grow at a faster pace than its industry competitors. MEI PHARMA INC is extremely liquid. Currently, the Quick Ratio is 11.01 which clearly shows the ability to cover any short-term cash needs. MEIP managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 22.05% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||0.45||0.0|
|Net Income ($mil)||-4.34||-5.77|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||53.57||45.92|
|Total Assets ($mil)||55.7||47.16|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||-110.47||0.0|
|Return on Assets||4.79||-44.23|
|Return on Equity||5.25||-50.08|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||36.77||34.16|
|Div / share||0.0||0.0|
|Book value / share||1.38||1.22|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||376769.0||266294.0|
SELL. This stock's P/E ratio indicates a premium compared to an average of 39.88 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.88. To use another comparison, its price-to-book ratio of 1.91 indicates a discount versus the S&P 500 average of 3.10 and a significant discount versus the industry average of 12.14. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|MEIP 44.00||Peers 39.88||MEIP 27.85||Peers 27.93|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
MEIP is trading at a premium to its peers.
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
MEIP is trading at a valuation on par to its peers.
|MEIP NM||Peers 25.67||MEIP NM||Peers 0.50|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
MEIP's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
MEIP's negative PEG ratio makes this valuation measure meaningless.
|MEIP 1.91||Peers 12.14||MEIP 109.83||Peers 10.47|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
MEIP is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
MEIP is expected to have an earnings growth rate that significantly exceeds its peers.
|MEIP 4.18||Peers 94.57||MEIP NA||Peers 233.22|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
MEIP is trading at a significant discount to its industry on this measurement.
Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.
The growth rate for MEIP is not available.